Literature DB >> 15829751

RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis.

Mahesh P Shanmugam1, Manisha Agarwal.   

Abstract

We report a case of Type 2A idiopathic parafoveal telangiectasis treated by Photodynamic Therapy (PDT), resulting in retinal pigment epithelial (RPE) atrophy corresponding to the size of the laser spot used. This raises a doubt regarding the safety of photodynamic therapy in CNVM secondary to type 2A parafoveal telangiectasis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15829751     DOI： 10.4103/0301-4738.15289

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN： 0301-4738            Impact factor:   1.848


  9 in total

1.  Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy.

Authors:  Noémi Maár; Erdem Ergun; Alexandra Luksch; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

2.  One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia.

Authors:  Nazimul Hussain; Taraprasad Das; Rohit Khanna; L S Mohan Ram; Kallukuri Sumasri
Journal:  Clin Ophthalmol       Date:  2007-12

3.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 4.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

5.  Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia.

Authors:  Pukhraj Rishi; Daraius Shroff; Ekta Rishi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-01-12       Impact factor: 3.117

6.  Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area.

Authors:  Nadia Artha Dewi; Mitsuko Yuzawa; Kasumi Tochigi; Akiyuki Kawamura; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

7.  Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.

Authors:  Subrata Mandal; Pradeep Venkatesh; Zahir Abbas; Rajpal Vohra; Satpal Garg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-03-08       Impact factor: 3.117

Review 8.  Macular Telangiectasia Type 2: A Comprehensive Review.

Authors:  Kiran Chandra Kedarisetti; Raja Narayanan; Michael W Stewart; Nikitha Reddy Gurram; Arshad M Khanani
Journal:  Clin Ophthalmol       Date:  2022-10-10

9.  Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane.

Authors:  Mahesh P Shanmugam; H M Mythri; Nitin S Shetty
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.